{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T15:16:15Z","timestamp":1793373375405,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.schres.2023.09.024","type":"journal-article","created":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T16:09:00Z","timestamp":1695744540000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?"],"prefix":"10.1016","author":[{"given":"Peter F.J.","family":"Schulte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene R.T.","family":"Veerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bert","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.A.M.","family":"Bogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Jongkind","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.schres.2023.09.024_bb0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/00004850-200403000-00007","article-title":"Experience of maintaining clozapine medication in patients with \u2018red-alert zone\u2019 neutropenia: long-term follow-up results","volume":"19","author":"Ahn","year":"2004","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.09.024_bb0010","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/BF00606410","article-title":"Clozapine-induced agranulocytosis: a situation report up to august 1976","volume":"11","author":"Anderman","year":"1977","journal-title":"Eur. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.schres.2023.09.024_bb0015","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/MOH.0b013e3282f15fb9","article-title":"Idiosyncratic drug-induced agranulocytosis or acute neutropenia","volume":"15","author":"Andr\u00e8s","year":"2008","journal-title":"Curr. Opin. Hematol."},{"key":"10.1016\/j.schres.2023.09.024_bb0020","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1097\/JCP.0000000000000478","article-title":"Clozapine underutilization in the treatment of schizophrenia: how can clozapine prescription rates be improved?","volume":"36","author":"Bogers","year":"2016","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2023.09.024_bb0025","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/acps.12989","article-title":"Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study","volume":"139","author":"Cho","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.schres.2023.09.024_bb0030","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1176\/appi.ajp.2012.12081036","article-title":"White blood cell monitoring during long-term clozapine treatment","volume":"170","author":"Cohen","year":"2013","journal-title":"Am. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2023.09.024_bb0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1097\/JCP.0000000000001699","article-title":"Hematological and other cancers in people using clozapine: analysis of Australian spontaneous reports between 1995 and 2020","volume":"43","author":"Dawson","year":"2023","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.09.024_bb0040","series-title":"Schizophrenia Research, S0920-9964(23)00184-6. Advance Online Publication","article-title":"Adverse drug reactions and their fatal outcomes in clozapine patients in VigiBase: comparing the top four reporting countries (US, UK, Canada and Australia)","author":"De Las Cuevas","year":"2023"},{"key":"10.1016\/j.schres.2023.09.024_bb0045","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1192\/bjp.188.3.255","article-title":"Rechallenge with clozapine following leucopenia or neutropenia during previous therapy","volume":"188","author":"Dunk","year":"2006","journal-title":"Br. J. Psychiatry J. Ment. Sci."},{"key":"10.1016\/j.schres.2023.09.024_bb0055","author":"European Medicines Agency"},{"key":"10.1016\/j.schres.2023.09.024_bb0060","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1192\/bjb.2018.67","article-title":"Barriers to using clozapine in treatment-resistant schizophrenia: systematic review","volume":"43","author":"Farooq","year":"2019","journal-title":"BJPsych Bull."},{"key":"10.1016\/j.schres.2023.09.024_bb0065","author":"FDA Drug Safety Communication"},{"key":"10.1016\/j.schres.2023.09.024_bb0070","author":"Food and Drug Administration"},{"key":"10.1016\/j.schres.2023.09.024_bb0075","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/YIC.0000000000000188","article-title":"Patient attitudes to clozapine initiation","volume":"32","author":"Gee","year":"2017","journal-title":"Int Clin Psychopharmacol."},{"issue":"7936","key":"10.1016\/j.schres.2023.09.024_bb0080","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(75)90135-X","article-title":"Letter: clozapine and agranulocytosis","volume":"2","author":"Griffith","year":"1975","journal-title":"Lancet."},{"issue":"Suppl. 3","key":"10.1016\/j.schres.2023.09.024_bb0085","first-page":"3","article-title":"Reducing clozapine-related morbidity and mortality: 5\u00a0years of experience with the Clozaril National Registry","volume":"59","author":"Honigfeld","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0090","doi-asserted-by":"crossref","first-page":"486","DOI":"10.7326\/0003-4819-146-7-200704030-00004","article-title":"Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences","volume":"146","author":"Hsieh","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.schres.2023.09.024_bb0095","first-page":"287","article-title":"Transient neutropenia induced by clozapine","volume":"28","author":"Hummer","year":"1992","journal-title":"Psychopharmacol. Bull."},{"issue":"7935","key":"10.1016\/j.schres.2023.09.024_bb0100","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/S0140-6736(75)90206-8","article-title":"Letter: clozapine and agranulocytosis","volume":"27;2","author":"Id\u00e4np\u00e4\u00e4n-Heikkil\u00e4","year":"1975","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.schres.2023.09.024_bb0105","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.eurpsy.2004.09.007","article-title":"Leukopenia in clozapine treated patients may be induced by other drugs: a case series","volume":"19","author":"Imbarlina","year":"2004","journal-title":"Eur. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.09.024_bb0110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1186\/s12888-016-1167-0","article-title":"Neutropenia and agranulocytosis during treatment of schizophrenia with clozapine versus other antipsychotics: an observational study in Iceland","volume":"12;16","author":"Ingimarsson","year":"2016","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0115","doi-asserted-by":"crossref","DOI":"10.1177\/20451253211072341","article-title":"Clozapine- and non-clozapine-associated neutropenia in patients with schizophrenia: a retrospective cohort study","volume":"12","author":"Johannsen","year":"2022","journal-title":"Ther Adv Psychopharmacol."},{"key":"10.1016\/j.schres.2023.09.024_bb0120","doi-asserted-by":"crossref","first-page":"756","DOI":"10.4088\/JCP.v67n0509","article-title":"Lithium and clozapine rechallenge: a retrospective case analysis","volume":"67","author":"Kanaan","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0125","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry."},{"issue":"19","key":"10.1016\/j.schres.2023.09.024_bb0130","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1001\/jama.1990.03450190018006","article-title":"Controversy grows over monitoring system for new schizophrenia drug","volume":"264","author":"Kleinerman","year":"1990","journal-title":"JAMA"},{"key":"10.1016\/j.schres.2023.09.024_bb0135","doi-asserted-by":"crossref","first-page":"837","DOI":"10.4088\/JCP.11m07244","article-title":"Clozapine-induced agranulocytosis in Finland, 1982-2007: long-term monitoring of patients is still warranted","volume":"73","author":"Lahdelma","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0140","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1177\/089719009000300401","article-title":"Pharmacists outraged by clozaril system","volume":"3","author":"Lee","year":"1990","journal-title":"Journal of Pharmacy Practice"},{"key":"10.1016\/j.schres.2023.09.024_bb0145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/JCP.0000000000001606","article-title":"The modernization of clozapine: a recapitulation of the past in the United States and the view forward","volume":"42","author":"Leung","year":"2022","journal-title":"J Clin Psychopharmacol."},{"key":"10.1016\/j.schres.2023.09.024_bb0150","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1017\/S0033291719000369","article-title":"The prevalence of agranulocytosis and related death in clozapine-treated patients: a comprehensive meta-analysis of observational studies","volume":"50","author":"Li","year":"2020","journal-title":"Psychol. Med."},{"key":"10.1016\/j.schres.2023.09.024_bb0155","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.schres.2017.08.041","article-title":"Sodium valproate and clozapine induced neutropenia: a case control study using register data","volume":"195","author":"Malik","year":"2018","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.schres.2023.09.024_bb0160","first-page":"32","article-title":"Agranulocytosis and phenothiazines","volume":"29","author":"Mandel","year":"1968","journal-title":"Dis. Nerv. Syst."},{"issue":"2","key":"10.1016\/j.schres.2023.09.024_bb0165","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1097\/MJT.0000000000000715","article-title":"Clozapine rechallenge after major adverse effects: clinical guidelines based on 259 cases","volume":"25","author":"Manu","year":"2018","journal-title":"Am. J. Ther."},{"issue":"11","key":"10.1016\/j.schres.2023.09.024_bb0170","doi-asserted-by":"crossref","first-page":"e1410","DOI":"10.4088\/JCP.14m09326","article-title":"Optimizing outcomes in clozapine rechallenge following neutropenia: a cohort analysis","volume":"76","author":"Meyer","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0175","series-title":"Clinical Chemist at Diagnostiek voor U in Eindhoven, Personal Communication, 2 August","author":"Michielsen","year":"2023"},{"key":"10.1016\/j.schres.2023.09.024_bb0180","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1007\/s00277-020-04215-y","article-title":"Clozapine-induced agranulocytosis","volume":"99","author":"Mijovic","year":"2020","journal-title":"Ann Hematol."},{"issue":"24","key":"10.1016\/j.schres.2023.09.024_bb0185","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.3748\/wjg.15.2960","article-title":"Systemic abnormalities in liver disease","volume":"15","author":"Minemura","year":"2009","journal-title":"World J Gastroenterol."},{"key":"10.1016\/j.schres.2023.09.024_bb0190","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1192\/bjp.175.6.576","article-title":"Active monitoring of 12,760 clozapine recipients in the UK and Ireland. Beyond pharmacovigilance","volume":"175","author":"Munro","year":"1999","journal-title":"Br J Psychiatry."},{"key":"10.1016\/j.schres.2023.09.024_bb0195","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/acps.12898","article-title":"Meta-analysis examining the epidemiology of clozapine-associated neutropenia","volume":"138","author":"Myles","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.09.024_bb0200","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0004867419833166","article-title":"A meta-analysis of controlled studies comparing the association between clozapine and other antipsychotic medications and the development of neutropenia","volume":"53","author":"Myles","year":"2019","journal-title":"Aust. N. Z. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0205","series-title":"Report for the National Institutes of Health, Publication No. 09-7473, 28 May. Bethesda, MD: National Cancer Institute.","article-title":"Common terminology criteria for adverse events v4.0","author":"National Cancer Institute","year":"2009"},{"key":"10.1016\/j.schres.2023.09.024_bb0210","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/hup.1181","article-title":"Haematological toxicity of clozapine and some other drugs used in psychiatry","volume":"26","author":"Nooijen","year":"2011","journal-title":"Hum. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2023.09.024_bb0215","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/schbul\/sbab006","article-title":"There is life after the UK clozapine central non-rechallenge database","volume":"47","author":"Oloyede","year":"2021","journal-title":"Schizophr Bull."},{"issue":"31","key":"10.1016\/j.schres.2023.09.024_bb0220","article-title":"Clozapine haematological monitoring for neutropenia: a global perspective","volume":"25","author":"Oloyede","year":"2022","journal-title":"Epidemiol Psychiatr Sci."},{"key":"10.1016\/j.schres.2023.09.024_bb0225","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/S2215-0366(22)00188-2","article-title":"Relaxation of the criteria for entry to the UK clozapine central non-rechallenge database: a modelling study","volume":"9","author":"Oloyede","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0230","first-page":"1","article-title":"Clinical impact of reducing the frequency of clozapine monitoring: controlled mirror-image cohort study","volume":"24","author":"Oloyede","year":"2023","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0235","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1136\/bmj.313.7067.1262a","article-title":"Reply from clozaril patient monitoring service","volume":"313","author":"O\u2019Sullivan","year":"1996","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.schres.2023.09.024_bb0240","first-page":"253","article-title":"The risk of suicide after clozapine discontinuation: cause for concern","volume":"27","author":"Patchan","year":"2015","journal-title":"Annals of clinical psychiatry: official journal of the American Academy of Clinical Psychiatrists"},{"issue":"2","key":"10.1016\/j.schres.2023.09.024_bb0245","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2165\/00003495-197815020-00003","article-title":"Drug-induced agranulocytosis","volume":"15","author":"Pisciotta","year":"1978","journal-title":"Drugs."},{"key":"10.1016\/j.schres.2023.09.024_bb0250","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1097\/JCP.0b013e318234eec2","article-title":"Late onset neutropenia associated with clozapine","volume":"31","author":"Raja","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2023.09.024_bb0255","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1056\/NEJMoa0806994","article-title":"Atypical antipsychotic drugs and the risk of sudden cardiac death","volume":"15;360","author":"Ray","year":"2009","journal-title":"N Engl J Med."},{"key":"10.1016\/j.schres.2023.09.024_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.03.048","article-title":"A brief history of clozapine in China with a look forward","author":"Ruan","year":"2023","journal-title":"Schizophrenia Research"},{"key":"10.1016\/j.schres.2023.09.024_bb0265","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1345\/aph.1G396","article-title":"The risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring","volume":"4","author":"Schulte","year":"2006","journal-title":"Ann. Pharmacother."},{"key":"10.1016\/j.schres.2023.09.024_bb0270","doi-asserted-by":"crossref","first-page":"225","DOI":"10.4103\/0019-5545.55097","article-title":"Prescribing practices of clozapine in India: results of a opinion survey of psychiatrists","volume":"51","author":"Shrivastava","year":"2009","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2023.09.024_bb0275","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12888-020-02592-2","article-title":"Clozapine rechallenge and initiation despite neutropenia - a practical, step-by-step guide","volume":"20","author":"Silva","year":"2020","journal-title":"BMC Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0280","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1111\/acps.13159","article-title":"Clozapine: a fine balance","volume":"141","author":"Siskind","year":"2020","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.09.024_bb0285","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1503\/jpn.200061","article-title":"Consensus statement on the use of clozapine during the COVID-19 pandemic","volume":"45","author":"Siskind","year":"2020","journal-title":"J. Psychiatry Neurosci."},{"key":"10.1016\/j.schres.2023.09.024_bb0290","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1002\/wps.20699","article-title":"20-year follow-up study of physical morbidity and mortality in relationship to antipsychotic treatment in a nationwide cohort of 62,250 patients with schizophrenia (FIN20)","volume":"19","author":"Taipale","year":"2020","journal-title":"World Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0295","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1046\/j.1440-1819.2001.904(1).x","article-title":"Late-onset neutropenia during clozapine treatment","volume":"55","author":"Tamam","year":"2001","journal-title":"Psychiatry & Clin Neuroscience"},{"key":"10.1016\/j.schres.2023.09.024_bb0300","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1192\/pb.24.12.450","article-title":"Clozapine \u2013 a survey of patient perceptions","volume":"24","author":"Taylor","year":"2000","journal-title":"Psychiatr. Bull."},{"issue":"1","key":"10.1016\/j.schres.2023.09.024_bb0305","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41537-022-00232-0","article-title":"Distinctive pattern of neutrophil count change in clozapine-associated, life-threatening agranulocytosis","volume":"14;8","author":"Taylor","year":"2022","journal-title":"Schizophrenia (Heidelb)"},{"issue":"5","key":"10.1016\/j.schres.2023.09.024_bb0310","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S2215-0366(22)00044-X","article-title":"Long-term treatment with clozapine and other antipsychotic drugs and the risk of haematological malignancies in people with schizophrenia: a nationwide case-control and cohort study in Finland","volume":"9","author":"Tiihonen","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.schres.2023.09.024_bb0320","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2018.05.046","article-title":"Prescriber and institutional barriers and facilitators of clozapine use: a systematic review","volume":"201","author":"Verdoux","year":"2018","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.schres.2023.09.024_bb0325","doi-asserted-by":"crossref","DOI":"10.1016\/j.schres.2023.03.032","article-title":"Risks and benefits of clozapine and lithium co-prescribing: a systematic review and expert recommendations","author":"Verdoux","year":"2023","journal-title":"Schizophrenia research"},{"issue":"4","key":"10.1016\/j.schres.2023.09.024_bb0330","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1093\/schbul\/sbad030","article-title":"Clozapine optimization: a delphi consensus guideline from the treatment response and resistance in psychosis working group","volume":"49","author":"Wagner","year":"2023","journal-title":"Schizophr. Bull."},{"issue":"6","key":"10.1016\/j.schres.2023.09.024_bb0335","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00001648-199711000-00014","article-title":"Mortality in current and former users of clozapine","volume":"8","author":"Walker","year":"1997","journal-title":"Epidemiology (Cambridge, Mass.)"},{"key":"10.1016\/j.schres.2023.09.024_bb0315","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1097\/JCP.0000000000001371","article-title":"Continuation of treatment with clozapine after an episode of neutropenia","volume":"41","author":"Tirupati","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.schres.2023.09.024_bb0340","series-title":"Clinical Chemist at the Clinical Chemistry Laboratory, St. Jansdal Hospital, in Harderwijk, Personal Communication, 22 March","author":"van der Weide","year":"2023"},{"issue":"10","key":"10.1016\/j.schres.2023.09.024_bb0345","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1176\/appi.ajp.2017.16091097","article-title":"Mortality and self-harm in association with clozapine in treatment-resistant schizophrenia","volume":"174","author":"Wimberley","year":"2017","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2023.09.024_bb0350","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/acps.13267","article-title":"Clozapine and mortality: a comparison with other antipsychotics in a nationwide Danish cohort study","volume":"143","author":"van der Zalm","year":"2021","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.schres.2023.09.024_bb0355","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1001\/archpsyc.1996.01830100104013","article-title":"Cost-effectiveness of clozapine monitoring after the first 6\u00a0months","volume":"53","author":"Zhang","year":"1996","journal-title":"Arch. Gen. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003353?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996423003353?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T05:33:46Z","timestamp":1696138426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996423003353"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":70,"alternative-id":["S0920996423003353"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2023.09.024","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of clozapine-associated agranulocytosis and mandatory white blood cell monitoring: Can the regulations be relaxed?","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2023.09.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}